Literature DB >> 18445579

Unraveling molecular complexity of phosphorylated human cardiac troponin I by top down electron capture dissociation/electron transfer dissociation mass spectrometry.

Vlad Zabrouskov1, Ying Ge, Jae Schwartz, Jeffery W Walker.   

Abstract

Cardiac troponin I (cTnI), the inhibitory subunit of the thin filament troponin-tropomyosin regulatory complex, is required for heart muscle relaxation during the cardiac cycle. Expressed only in cardiac muscle, cTnI is widely used in the clinic as a serum biomarker of cardiac injury. In vivo function of cTnI is influenced by phosphorylation and proteolysis; therefore analysis of post-translational modifications of the intact protein should greatly facilitate the understanding of cardiac regulatory mechanisms and may improve cTnI as a disease biomarker. cTnI (24 kDa, pI approximately 9.5) contains twelve serine, eight threonine, and three tyrosine residues, which presents a challenge for unequivocal identification of phosphorylation sites and quantification of positional isomers. In this study, we used top down electron capture dissociation and electron transfer dissociation MS to unravel the molecular complexity of cTnI purified from human heart tissue. High resolution MS spectra of human cTnI revealed a high degree of heterogeneity, corresponding to phosphorylation, acetylation, oxidation, and C-terminal proteolysis. Thirty-six molecular ions of cTnI were detected in a single ESI/FTMS spectrum despite running as a single sharp band on SDS-PAGE. Electron capture dissociation of monophosphorylated cTnI localized two major basal phosphorylation sites: a well known site at Ser(22) and a novel site at Ser(76)/Thr(77), each with partial occupancy (Ser(22): 53%; Ser(76)/Thr(77): 36%). Top down MS(3) analysis of diphosphorylated cTnI revealed occupancy of Ser(23) only in diphosphorylated species consistent with sequential (or ordered) phosphorylation/dephosphorylation of the Ser(22/23) pair. Top down MS of cTnI provides unique opportunities for unraveling its molecular complexity and for quantification of phosphorylated positional isomers thus allowing establishment of the relevance of such modifications to physiological functions and disease status.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18445579     DOI: 10.1074/mcp.M700524-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  66 in total

1.  Phosphorylation, but not alternative splicing or proteolytic degradation, is conserved in human and mouse cardiac troponin T.

Authors:  Jiang Zhang; Han Zhang; Serife Ayaz-Guner; Yi-Chen Chen; Xintong Dong; Qingge Xu; Ying Ge
Journal:  Biochemistry       Date:  2011-06-15       Impact factor: 3.162

2.  Why is it important to analyze the cardiac sarcomere subproteome?

Authors:  R John Solaro; Chad M Warren; Sarah B Scruggs
Journal:  Expert Rev Proteomics       Date:  2010-06       Impact factor: 3.940

3.  Preconcentration and detection of the phosphorylated forms of cardiac troponin I in a cascade microchip by cationic isotachophoresis.

Authors:  Danny Bottenus; Mohammad Robiul Hossan; Yexin Ouyang; Wen-Ji Dong; Prashanta Dutta; Cornelius F Ivory
Journal:  Lab Chip       Date:  2011-09-21       Impact factor: 6.799

4.  Tissue procurement strategies affect the protein biochemistry of human heart samples.

Authors:  Lori A Walker; Allen M Medway; John S Walker; Joseph C Cleveland; Peter M Buttrick
Journal:  J Muscle Res Cell Motil       Date:  2010-12-24       Impact factor: 2.698

5.  Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure.

Authors:  Jiang Zhang; Moltu J Guy; Holly S Norman; Yi-Chen Chen; Qingge Xu; Xintong Dong; Huseyin Guner; Sijian Wang; Takushi Kohmoto; Ken H Young; Richard L Moss; Ying Ge
Journal:  J Proteome Res       Date:  2011-07-28       Impact factor: 4.466

6.  Top-down high-resolution mass spectrometry of cardiac myosin binding protein C revealed that truncation alters protein phosphorylation state.

Authors:  Ying Ge; Inna N Rybakova; Qingge Xu; Richard L Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-16       Impact factor: 11.205

Review 7.  Protein phosphorylation and signal transduction in cardiac thin filaments.

Authors:  R John Solaro; Tomoyoshi Kobayashi
Journal:  J Biol Chem       Date:  2011-01-21       Impact factor: 5.157

8.  Top-down targeted proteomics for deep sequencing of tropomyosin isoforms.

Authors:  Ying Peng; Xin Chen; Han Zhang; Qingge Xu; Timothy A Hacker; Ying Ge
Journal:  J Proteome Res       Date:  2012-12-20       Impact factor: 4.466

Review 9.  Myofilament dysfunction in cardiac disease from mice to men.

Authors:  Nazha Hamdani; Monique de Waard; Andrew E Messer; Nicky M Boontje; Viola Kooij; Sabine van Dijk; Amanda Versteilen; Regis Lamberts; Daphne Merkus; Cris Dos Remedios; Dirk J Duncker; Attila Borbely; Zoltan Papp; Walter Paulus; Ger J M Stienen; Steven B Marston; Jolanda van der Velden
Journal:  J Muscle Res Cell Motil       Date:  2009-01-13       Impact factor: 2.698

10.  Cardiac fibroblasts inhibit β-adrenoceptor-dependent connexin43 expression in neonatal rat cardiomyocytes.

Authors:  A Salameh; H Djilali; K Blanke; J Gonzalez Casanova; S von Salisch; A Savtschenko; S Dhein; I Dähnert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-03-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.